|
Nov 29
|
17 Best European Countries to Move to from the USA
|
|
Nov 29
|
AstraZeneca advances scientific leadership in hematology at ASH 2023
|
|
Nov 28
|
15 Hardest Countries to Get Citizenship in Europe
|
|
Nov 28
|
UPDATE 2-White House urges RSV immunization makers to meet demand
|
|
Nov 28
|
30 Countries with the Highest Quality of Life Heading into 2024
|
|
Nov 27
|
Tesla sues Sweden in bid to avoid hit from strikes
|
|
Nov 27
|
Theseus (THRX) Up 57% in a Month on Strategic Restructuring Plan
|
|
Nov 27
|
Do AstraZeneca's (LON:AZN) Earnings Warrant Your Attention?
|
|
Nov 26
|
12 Best Diabetes Stocks To Buy Now
|
|
Nov 26
|
15 Best Drug Stocks To Invest In
|
|
Oct 24
|
AstraZeneca asks the FDA to let adults give themselves the annual flu vaccine
|
|
Oct 24
|
US Food and Drug Administration accepts for review AstraZeneca’s Supplemental Biologics License Application for self-administration of FLUMIST® QUADRIVALENT (Influenza Vaccine Live, Intranasal)
|
|
Oct 24
|
Alexion, AstraZeneca Rare Disease, concludes Letter of Intent (LOI) with the pan-Canadian Pharmaceutical Alliance (pCPA) for Ultomiris for the treatment of patients with paroxysmal nocturnal hemoglobinuria or atypical hemolytic uremic syndrome
|
|
Oct 24
|
US FDA accepts AstraZeneca's self-administered flu vaccine for review
|
|
Oct 23
|
Datopotamab deruxtecan improved progression-free survival vs. chemotherapy in patients with previously treated non-small cell lung cancer in TROPION-Lung01 Phase III trial
|
|
Oct 23
|
ENHERTU® (fam-trastuzumab deruxtecan-nxki) Demonstrated Clinically Meaningful Survival Across Multiple HER2-Expressing Advanced Solid Tumors in DESTINY-PanTumor02 Phase II Trial
|
|
Oct 23
|
AstraZeneca hails ‘clinically meaningful’ cancer drug trial results
|
|
Oct 23
|
Datopotamab deruxtecan significantly extended progression-free survival vs. chemotherapy in patients with HR-positive, HER2-low or negative breast cancer in TROPION-Breast01 Phase III trial
|
|
Oct 23
|
AstraZeneca PLC's (LON:AZN) Stock Has Shown Weakness Lately But Financial Prospects Look Decent: Is The Market Wrong?
|
|
Oct 23
|
Merck (MRK) to Report Q3 Earnings: What's in the Cards?
|